Chemotherapy advances in small-cell lung cancer

Journal of Thoracic Disease

Volumn 5, Issue SUPPL.5, 2013, Pages

  Chan, Bryan A ^a,b   Coward, Jermaine I G ^a,b,c  

^a MATER ADULT HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

Author keywords

Amrubicin; Belotecan; Picoplatin; Relapsed SCLC; Small cell lung cancer (SCLC)

Indexed keywords

AMRUBICIN; BELOTECAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; PICOPLATIN; PLACEBO; TOPOTECAN; VINCRISTINE;

ANEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSOLIDATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RECOMMENDED DRUG DOSE; REVIEW; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION;

EID: 84896264786     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.07.43     Document Type: Review

References (107)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011;378:1741-55.
3. Kato Y, Ferguson TB, Bennett DE, et al. Oat cell carcinoma of the lung. A review of 138 cases. Cancer 1969;23:517-24.
4. Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2009;(4):CD001990.
5. Miller AB, Fox W, Tall R. Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet 1969;2:501-5.
6. Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969;46:516-25.
7. Lowenbraun S, Bartolucci A, Smalley RV, et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 1979;44:406-13.
8. Livingston RB, Moore TN, Heilbrun L, et al. Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Ann Intern Med 1978;88:194-9.
9. Hann CL, Ettinger DS. The change in pattern and pathology of small cell lung cancer. In: Govindan R. eds. American Society of Clinical Oncology. Alexandria, VA, 2009.
10. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-801.
11. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-77.
12. Australian Institute of Health and Welfare & Cancer Australia 2011. Lung cancer in Australia: an overview. Cancer series no. 64. Canberra: AIHW, 2011.
13. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-84.
14. Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 1973;2:63-5.
15. Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. J Natl Compr Canc Netw 2013;11:78-98.
16. Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012;2:798-811.
17. Rosell R, Wannesson L. A genetic snapshot of small cell lung cancer. Cancer Discov 2012;2:769-71.
18. Haddadin S, Perry MC. History of small-cell lung cancer. Clin Lung Cancer 2011;12:87-93.
19. Barnard WG. The nature of the "oat-celled sarcoma" of the mediastinum. J Pathol 1926;29:241-4.
20. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973;4:31-42.
21. Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007;12:1096-104.
22. Johnson DH. Management of small cell lung cancer: current state of the art. Chest 1999;116:525S-530S.
23. Watson WL, Berg JW. Oat cell lung cancer. Cancer 1962;15:759-68.
24. Levine B, Weisberger AS. The response of various types of bronchogenic carcinoma to nitrogen mustard. Ann Intern Med 1955;42:1089-96.
25. Wolf J, Spear P, Yesner R, et al. Nitrogen mustard and the steroid hormones in the treatment of inoperable bronchogenic carcinoma. Am J Med 1960;29:1008-16.
26. Wolf J, Yesner R, Patno ME. Evaluation of nitrogen mustard in prolonging life of patients with bronchogenic carcinoma. Cancer Chemother Rep 1962;16:473-5.
27. Medical Research Council Lung Cancer Working Party. Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Br J Cancer 1979;40:1-10.
28. Joss RA, Cavalli F, Goldhirsch A, et al. New drugs in small-cell lung cancer. Cancer Treat Rev 1986;13:157-76.
29. Goldhirsch A, Joss R, Cavalli F, et al. Etoposide as single agent and in combination chemotherapy of bronchogenic carcinoma. Cancer Treat Rev 1982;9:85-90.
30. Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471-7.
31. Evans WK, Shepherd FA, Feld R, et al. First-line therapy with VP-16 and cisplatin for small-cell lung cancer. Semin Oncol 1986;13:17-23.
32. Loehrer PJ Sr, Einhorn LH, Greco FA. Cisplatin plus etoposide in small cell lung cancer. Semin Oncol 1988;15:2-8.
33. Cavalli F, Sonntag RW, Jungi F, et al. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 1978;62:473-5.
34. Jett JR, Everson L, Therneau TM, et al. Treatment of limited-stage smallcell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J Clin Oncol 1990;8:33-8.
35. Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988;15:278-99.
36. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-91.
37. Fukuoka M, Furuse K, Saijo N, et al. Randomized t r i a l of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-61.
38. Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-72.
39. Shaw EG, Frytak S, Eagan RT, et al. Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma of the lung. Am J Clin Oncol 1996;19:154-8.
40. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601-7.
41. Pujol JL, Carestia L, Daurès JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8-15.
42. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30:1692-8.
43. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
44. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-43.
45. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-5.
46. Kim SJ, Kim JS, Kim SC, et al. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer. Lung Cancer 2010;68:446-9.
47. Hong J, Jung M, Kim YJ, et al. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol 2012;69:215-20.
48. Lim S, Cho BC, Jung JY, et al. Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. Lung Cancer 2013;80:313-8.
49. Ohe Y, Negoro S, Matsui K, et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2005;16:430-6.
50. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:253-8.
51. Kobayashi M, Matsui K, Iwamoto Y, et al. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301. J Thorac Oncol 2010;5:1075-80.
52. O'Brien ME, Konopa K, Lorigan P, et al. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer-EORTC 08062. Eur J Cancer 2011;47:2322-30.
53. Kimura T, Kudoh S, Hirata K. Review of the management of relapsed smallcell lung cancer with amrubicin hydrochloride. Clin Med Insights Oncol 2011;5:23-34.
54. Chonnam National University Hospital. Trial of belotecan/cisplatin in chemotherapy naive small cell lung cancer patient (COMBAT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 July 9]. Available online: http://clinicaltrials.gov/show/NCT00826644
55. Hanada M, Mizuno S, Fukushima A, et al. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase IIDNA complex. Jpn J Cancer Res 1998;89:1229-38.
56. Metro G, Duranti S, Fischer MJ, et al. Emerging drugs for small cell lung cancer--an update. Expert Opin Emerg Drugs 2012;17:31-6.
57. Higashiguchi M, Suzuki H, Hirashima T, et al. Long-term amrubicin chemotherapy for small-cell lung cancer. Anticancer Res 2012;32:1423-7.
58. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24.
59. Noro R, Yoshimura A, Yamamoto K, et al. Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer. Anticancer Res 2013;33:1117-23.
60. Sumitomo Pharmaceutical (Suzhou) Co., Ltd. Phase 3 study of amrubicin with cisplatin versus etoposide-cisplatin for extensive disease small cell lung cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 July 10]. Available online: http:// clinicaltrials.gov/ct2/show/NCT00660504
61. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593- -a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-22.
62. Rossi A, Garassino MC, Cinquini M, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010;70:119-28.
63. Davies AM, Evans WK, Mackay JA, et al. Treatment of recurrent small cell lung cancer. Hematol Oncol Clin North Am 2004;18:387-416.
64. Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988;6:1264-70.
65. Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987;23:1409-11.
66. Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987;23:1697-9.
67. Glisson BS. Recurrent small cell lung cancer: update. Semin Oncol 2003;30:72-8.
68. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67.
69. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7.
70. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-92.
71. Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998;77:347-51.
72. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-9.
73. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003;21:1550-5.
74. Furuse K, Kubota K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology 1996;53:169-72.
75. Goto K, Sekine I, Nishiwaki Y, et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 2004;91:659-65.
76. Fujita A, Takabatake H, Tagaki S, et al. Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology 2000;59:105-9.
77. Groen HJ, Fokkema E, Biesma B, et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol 1999;17:927-32.
78. Garassino MC, Torri V, Michetti G, et al. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multiinstitutional retrospective analysis. Lung Cancer 2011;72:378-83.
79. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-53.
80. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-6.
81. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as secondline therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:2598-603.
82. Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of singleagent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011;29:287-93.
83. Von Pawel J, Jotte R, Spigel DR, et al. Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC). J Clin Oncol 2011;29:abstr 7000.
84. Treat J, Schiller J, Quoix E, et al. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer 2002; 38 Suppl 8:S13-8.
85. Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009;27:2046-51.
86. Ciuleanu T, Samarzjia M, Demidchik Y, et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol 2010;28:abstr 7002.
87. Rhee CK, Lee SH, Kim JS, et al. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer. Lung Cancer 2011;72:64-7.
88. Jeong J, Cho BC, Sohn JH, et al. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer 2010;70:77-81.
89. Kim GM, Kim YS, Ae Kang Y, et al. Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients. J Thorac Oncol 2012;7:731-6.
90. Schmittel A, Knödler M, Hortig P, et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007;55:109-13.
91. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
92. Ettinger DS. Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific? J Thorac Oncol 2007;2:160-5.
93. Shibayama T, Hotta K, Takigawa N, et al. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Lung Cancer 2006;53:189-95.
94. Nogami N, Hotta K, Kuyama S, et al. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensivedisease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. Lung Cancer 2011;74:80-4.
95. Holford J, Sharp SY, Murrer BA, et al. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998;77:366-73.
96. William WN Jr, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 2011;8:611-9.
97. Mistry P, Kelland LR, Abel G, et al. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991;64:215-20.
98. Tang CH, Parham C, Shocron E, et al. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother Pharmacol 2011;67:1389-400.
99. Köster W, Heider A, Niederle N, et al. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol 2007;2:312-6.
100. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
101. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
102. Socinski MA, Raju RN, Neubauer M, et al. Pemetrexed in relapsed smallcell lung cancer and the impact of shortened vitamin supplementation leadin time: results of a phase II trial. J Thorac Oncol 2008;3:1308-16.
103. Jalal S, Ansari R, Govindan R, et al. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol 2009;4:93-6.
104. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-96.
105. Nicolson MC, Fennell DA, Ferry D, et al. Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non-Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial. J Thorac Oncol 2013;8:930-939.
106. Ibe T, Shimizu K, Nakano T, et al. High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes. J Surg Oncol 2010;102:11-7.
107. Monica V, Scagliotti GV, Ceppi P, et al. Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. Clin Cancer Res 2009;15:7547-7552.